Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Common Equity (2016 - 2025)

Vanda Pharmaceuticals' Common Equity history spans 17 years, with the latest figure at $327.2 million for Q4 2025.

  • On a quarterly basis, Common Equity fell 39.25% to $327.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $327.2 million, a 39.25% decrease, with the full-year FY2025 number at $327.2 million, down 39.25% from a year prior.
  • Common Equity hit $327.2 million in Q4 2025 for Vanda Pharmaceuticals, down from $466.0 million in the prior quarter.
  • Over the last five years, Common Equity for VNDA hit a ceiling of $544.9 million in Q4 2023 and a floor of $327.2 million in Q4 2025.
  • Historically, Common Equity has averaged $506.1 million across 5 years, with a median of $513.5 million in 2022.
  • Biggest five-year swings in Common Equity: grew 12.31% in 2021 and later crashed 39.25% in 2025.
  • Tracing VNDA's Common Equity over 5 years: stood at $504.9 million in 2021, then increased by 4.41% to $527.2 million in 2022, then grew by 3.36% to $544.9 million in 2023, then fell by 1.17% to $538.5 million in 2024, then crashed by 39.25% to $327.2 million in 2025.
  • Business Quant data shows Common Equity for VNDA at $327.2 million in Q4 2025, $466.0 million in Q3 2025, and $486.3 million in Q2 2025.